Zentalis Pharmaceuticals, Inc. 8-K

What Happened

• On May 12, 2026, Zentalis Pharmaceuticals, Inc. (ZNTL) announced its financial results for the quarter ended March 31, 2026 via a press release (furnished as Exhibit 99.1 to the Form 8‑K).
• The company also furnished a corporate presentation (Exhibit 99.2) that spokespersons plan to use in conferences and investor/analyst meetings beginning May 12, 2026.
• The press release and presentation are furnished and incorporated by reference in the Form 8‑K but are expressly marked as not “filed” for purposes of Section 18 of the Exchange Act.

Key Details

• Announcement date: May 12, 2026.
• Reporting period: Quarter ended March 31, 2026.
• Materials: Press release (Exhibit 99.1) and Corporate Presentation (Exhibit 99.2) were furnished with the 8‑K.
• Disclosure status: Information is furnished (Regulation FD disclosure) and not subject to Section 18 filing liabilities or automatic incorporation by reference into other filings.

Why It Matters

• For investors, this 8‑K signals the release of Zentalis’s quarterly results and related investor presentation—primary sources for updates on revenue, expenses, cash position, guidance, and program progress.
• Because the Form 8‑K furnishes the materials (rather than “files” them), investors should review the attached press release and presentation directly for the specific financial figures and business updates referenced.
• The company’s plan to present the slides to investors and analysts means the same information will be repeated in upcoming investor events; monitor those presentations and any subsequent filings for additional details.